

# Polytetrafluoroethylene Vascular Graft as a Rescuer of Short Renal Vessels During Kidney Transplantation

Gholam Hossein Naderi,<sup>1</sup> Darab Mehraban,<sup>2</sup> Seyed Mohammad Kazemeyni,<sup>2</sup> Seyed Reza Yahyazadeh,<sup>2</sup> Amir Hossein Latif<sup>3</sup>

Keywords: kidney transplantation, polytetrafluoroethylene, blood vessel prosthesis, renal artery, renal vein

Urol J. 2009;6:47-9.  
www.uj.unrc.ir

## INTRODUCTION

Short or damaged renal vessels represent a serious challenge during kidney transplantation. The increasing risk of thrombosis, bleeding, or compromised kidney function often leads to declining the donated kidneys with damaged vessels.<sup>(1)</sup> We here describe 5 kidney transplantations in which a polytetrafluoroethylene (PTFE) vascular graft was interposed between the short renal vessels and the recipient's vessels. The PTFE graft was used both as arterial and venous grafts. We could not use either of the described techniques as a means of lengthening the vessels<sup>(2,3)</sup>; therefore, we used a synthetic vascular graft for our patients.

Delaware, USA) as an arterial graft in 2 kidney allograft recipients and as a venous graft in 3 others with short donor's renal vessels during kidney transplantation (Figure). In recipients 1 and 2, the graft was used to make end-to-end (recipient 1) and end-to-side (recipient 2) anastomoses between the donor's renal artery and the recipient's external iliac artery (Table 1). In these 2 cases, the donor's renal veins were anastomosed end-to-side to the external iliac veins.

In the 3 other recipients, shortness of the donor's renal veins made us use the PTFE vascular graft as a venous graft for lengthening the veins and making end-to-end anastomoses between the renal veins and external iliac veins (Table 2). The donor's renal arteries and external iliac arteries were successfully anastomosed by end-to-side anastomoses without any problems.

## TECHNIQUE

The patients' characteristics are listed in Table 1. We used the PTFE vascular graft (GORE-TEX, WL Gore & Associates, Newark,

<sup>1</sup>Department of Kidney Transplantation, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

<sup>2</sup>Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

<sup>3</sup>Students' Scientific Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Corresponding Author:  
GholamHossein Naderi, MD  
Department of Kidney

Transplantation, Shariati Hospital, Jalal-e-AI-e-Ahmad Hwy, Tehran, Iran

Tel: +98 21 8490 2406

Fax: +98 21 8863 3039

E-mail: gh\_naderi2000@yahoo.com


Received April 2008

Accepted November 2008

**Table 1.** Demographic and Clinical Characteristics of Kidney Allograft Recipients With Polytetrafluoroethylene Graft for Renal Vessels\*

Patient	Age, y	Sex	Primary Disease	Donor Source	Graft Indication
1	36	Male	GN	Living Unrelated	Excision of the artery because of lymphocele and narrowing
2	36	Male	Graft Loss	Cadaver	Shortness of the donor's accessory renal artery
3	53	Female	VUR and ureteral Obstruction	Living Unrelated	Shortness of donor's renal vein
4	53	Male	Graft Loss	Living Unrelated	Shortness of donor's renal vein
5	36	Male	Hypertension	Living Unrelated	Shortness of donor's renal vein

\*GN indicates glomerulonephritis and VUR, vesicoureteral reflux.



**Left**, Ischemia in the lower pole of the transplanted kidney was seen before the use of polytetrafluoroethylene graft. **Right**, All ischemic manifestations disappeared when the graft was used for anastomosis of the accessory renal artery with the external iliac artery (recipient 2).

**Table 2.** Outcome of Kidney Transplantation and Polytetrafluoroethylene (PTFE) Graft for Renal Vessels

Patient	Graft Type	PTFE Length, cm	PTFE Diameter, cm	Anastomosis Type	Serum Creatinine at Discharge, mg/dL	Follow-up, y	Last Serum Creatinine, mg/dL
1	Arterial	4	0.6	End-to-end, external iliac artery	1.70	6.0	1.40
2	Arterial	7	0.6	End-to-side, external iliac artery	1.60	2.0	1.20
3	Venous	4	0.6	End-to-end, external iliac vein	1.60	1.0	1.30
4	Venous	4	0.6	End-to-end, external iliac vein	1.10	1.0	1.20
5	Venous	4	0.6	End-to-end, external iliac vein	1.00	0.5	1.12

We did not use anticoagulant drugs in any of our patients, and they received only conventional immunosuppressive drugs.

## RESULTS

The outcomes are listed in Table 2. The experience of using the PTFE vascular graft as venous and arterial grafts during kidney transplantation was successful in all of our patients, and postoperative Doppler ultrasonography showed no complications in any of them. The median follow-up period was 1.0 year (range, 0.5 to 6.0 years). All of the signs and symptoms existing due to end-stage renal failure before the transplantation were completely disappeared after the operation in our patients, and none of them experienced any kind of rejection. Serum creatinine level decreased remarkably and the median last creatinine level among these patients was 1.20 mg/dL (range, 1.12 mg/dL to 1.40 mg/dL). No complications were reported during the follow-up period.

## DISCUSSION

Short and damaged vessels extend the length of the warm ischemia time during renal vessel anastomosis in kidney transplantation. Various methods have been described to repair these vessels, but most of them may cause serious adverse effects.<sup>(4)</sup> The use of synthetic vascular grafts such as PTFE can solve the problems without those adverse effects. However, there are few reported cases in which a PTFE vascular graft was used for reconstruction of the short or damaged renal vessels during kidney transplantation. Delpin described 2 cases of short renal vein repairs with the use of PTFE vascular grafts without any complications.<sup>(5)</sup> In another report, Blacklock and colleagues<sup>(6)</sup> described a successful case of renal autotransplantation with interposed PTFE vascular graft as a cure of loin pain/hematuria syndrome. In another study, Kamel and colleagues<sup>(7)</sup> described 3 cases in which the PTFE graft was used as a vascular graft during kidney transplantation. They did not report any

technical problems or complications.

Our report added 5 new cases of PTFE graft use as a renal vascular graft, as both arterial and venous grafts, to what has been described to date. Four of our patients were receiving a kidney from living unrelated donors. The use of PTFE vascular graft as a renal venous graft in 3 of the patients adds another successful experience to what has been reported previously. Since there were only 2 reported cases of PTFE usage as a renal venous graft before,<sup>(5)</sup> we hope that by adding 3 new cases to the literature, its utilization in the future will increase. In our cases, the patients had uneventful follow-up periods that convince the surgeons to use it more assuredly. Systemic heparin was not used for any of the patients due to the reported increased risk of bleeding and the greater need for blood transfusion in transplant surgeries associated with heparin use.<sup>(8)</sup>

Our report provides an easy-to-use technique for solving the problems of short and damaged renal vessels during kidney transplantation. Although we did not experience any complications in the use of the PTFE grafts, there is little information in the literature pertaining to the long-term outcome of the PTFE grafts in kidney transplantation. Most of the long-term data on the use of the PTFE grafts originate from its application in lower limb revascularization.<sup>(9,10)</sup> Those grafts tend to be long with a slow blood flow, while the PTFE grafts in kidney transplantation are short in length and have a high blood flow. Therefore, it seems renal PTFE grafts may have better long-term results than those used in lower limb revascularization.

#### ACKNOWLEDGMENT

We would like to appreciate all of the patients who let us use and publish their medical information. This study was supported by neither the manufacturers nor the importer companies. The PTFE grafts were provided by cardiac

surgery department of our hospital.

#### CONFLICT OF INTEREST

None declared.

#### REFERENCES

1. Goel MC, Flechner SM, El-Jack M, et al. Salvage of compromised renal vessels in kidney transplantation using third-party cadaveric extenders: impact on posttransplant anti-HLA antibody formation. *Transplantation*. 2004;77:1899-902.
2. Barry JM, Morris PJ. Surgical techniques of renal transplantation. In: Morris PJ, editor. *Kidney transplantation, principles and practice*. 5th ed. Philadelphia: WB Saunders; 2001. p. 159-71.
3. Simforoosh N, Aminsharifi A, Tabibi A, Fattahi M, Mahmoodi H, Tavakoli M. Right laparoscopic donor nephrectomy and the use of inverted kidney transplantation: an alternative technique. *BJU Int*. 2007;100:1347-50.
4. Baptista-Silva JC, Medina-Pestana JO, Verissimo MJ, Castro MJ, Demuner MS, Signorelli MF. Right renal vein elongation with the inferior vena cava for cadaveric kidney transplants. An old neglected surgical approach. *Int Braz J Urol*. 2005;31:519-25.
5. Delpin ES. Brief report: successful extension of the transplant renal vein with a synthetic vascular graft. *Bol Asoc Med P R*. 1997;89:206-7.
6. Blacklock AR, Raabe AL, Lam FT. Renal auto-transplantation with interposed PTFE arterial graft: not necessarily a cure for loin pain/haematuria syndrome. *J R Coll Surg Edinb*. 1999;44:134.
7. Kamel MH, Thomas AA, Mohan P, Hickey DP. Renal vessel reconstruction in kidney transplantation using a polytetrafluoroethylene (PTFE) vascular graft. *Nephrol Dial Transplant*. 2007;22:1030-2.
8. Mohan P, Murphy DM, Counihan A, Cunningham P, Hickey DP. The role of intraoperative heparin in cyclosporine treated cadaveric renal transplant recipients. *J Urol*. 1999;162:682-4.
9. Prager M, Polterauer P, Bohmig HJ, et al. Collagen versus gelatin-coated Dacron versus stretch polytetrafluoroethylene in abdominal aortic bifurcation graft surgery: results of a seven-year prospective, randomized multicenter trial. *Surgery*. 2001;130:408-14.
10. Prager MR, Hoblaj T, Nanobashvili J, et al. Collagen-versus gelatine-coated Dacron versus stretch PTFE bifurcation grafts for aortoiliac occlusive disease: long-term results of a prospective, randomized multicenter trial. *Surgery*. 2003;134:80-5.